Seminars article
Advances in medical imaging for the diagnosis and management of common genitourinary cancers☆,☆☆

https://doi.org/10.1016/j.urolonc.2017.04.014Get rights and content
Under a Creative Commons license
open access

Abstract

Medical imaging of the 3 most common genitourinary (GU) cancers—prostate adenocarcinoma, renal cell carcinoma, and urothelial carcinoma of the bladder—has evolved significantly during the last decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector computed tomography and multiparametric MRI with diffusion-weighted imaging are the main imaging modalities for renal cell carcinoma and urothelial carcinoma, and although multiparametric MRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose-PET and sodium fluoride-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review provides an overview of the latest advances in the imaging of these 3 major GU cancers.

Keywords

Renal cell carcinoma
Bladder urothelial carcinoma
Prostate adenocarcinoma
CT
MRI
PET

Cited by (0)

☆

The content is the responsibility of the presenter and does not necessarily represent the official views of the National Institutes of Health.

☆☆

This research was supported by the NIH Clinical Center Intramural Research Program.

Published by Elsevier Inc.